Liqrev FDA Approval History
Last updated by Judith Stewart, BPharm on June 26, 2023.
FDA Approved: Yes (First approved April 28, 2023)
Brand name: Liqrev
Generic name: sildenafil citrate
Dosage form: Oral Suspension
Company: CMP Pharma, Inc.
Treatment for: Pulmonary Arterial Hypertension
Liqrev (sildenafil citrate) is a ready-made oral liquid formulation of the approved phosphodiesterase-5 (PDE-5) inhibitor sildenafil used for the treatment of pulmonary arterial hypertension.
- Liqrev is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening.
- Sildenafil works in the treatment of PAH by inhibiting the PDE-5 enzyme. Inhibition of the PDE-5 enzyme increases the concentration of a signaling molecule known as cyclic guanosine monophosphate (cGMP), which leads to relaxation of vascular smooth muscles, dilation of blood vessels, and improved blood flow.
- The Liqrev liquid oral suspension of sildenafil has been formulated for patients who have dysphagia or difficulty swallowing tablets. Previously, liquid formulations of sildenafil were compounded from crushed tablets. Liqrev is a ready-made product with a strawberry flavor, available in 122 mL bottles with a 24-month shelf life.
- Liqrev is administered orally three times a day.
- Warnings and precautions associated with Liqrev include vasodilation effects, and hearing or visual impairment. Patients should never take Liqrev with any nitrate (nitroglycerin, isosorbide mononitrate or dinitrate) or guanylate cyclase stimulator (riociguat) medicines due to the risk of hypotension.
- Sildenafil is also FDA approved under the brand name Viagra for the treatment of erectile dysfunction. Patients who take Liqrev should not take Viagra or any other PDE-5 inhibitors.
- Common adverse reactions include headache, dyspepsia, flushing, pain in limb, myalgia, back pain and diarrhea.
Development timeline for Liqrev
| Date | Article |
|---|---|
| Jun 21, 2023 | Approval CMP Pharma, Inc Announces that Liqrev, the First and Only Ready-made FDA-approved Liquid Suspension of Sildenafil is Now Available |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
